Y-Biologics (XKRX:338840) Cash-to-Debt : N/A (As of Mar. 2024)

View and export this data going back to 2023. Start your Free Trial

What is Y-Biologics Cash-to-Debt?

Cash to Debt Ratio measures the financial strength of a company. It is calculated as a company's cash, cash equivalents, and marketable securities divide by its debt. Y-Biologics's cash to debt ratio for the quarter that ended in Mar. 2024 was N/A.

The historical rank and industry rank for Y-Biologics's Cash-to-Debt or its related term are showing as below:

During the past 6 years, Y-Biologics's highest Cash to Debt Ratio was 7.23. The lowest was 0.00. And the median was 4.95.

XKRX:338840's Cash-to-Debt is not ranked ^*
in the Biotechnology industry.
Industry Median: 6.89
* Ranked among companies with meaningful Cash-to-Debt only.

Y-Biologics Cash-to-Debt Historical Data

The historical data trend for Y-Biologics's Cash-to-Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Note: An indication of "No Debt" does not necessarily mean that the company has no debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.

* Premium members only.

Y-Biologics Cash-to-Debt Chart

Y-Biologics Annual Data

Trend

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Cash-to-Debt

Get a 7-Day Free Trial

13.57

4.67

6.24

2.85

2.63

Y-Biologics Quarterly Data
	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Cash-to-Debt	Get a 7-Day Free Trial				5.03	4.95	3.53	7.23	N/A

Competitive Comparison of Y-Biologics's Cash-to-Debt

For the Biotechnology subindustry, Y-Biologics's Cash-to-Debt, along with its competitors' market caps and Cash-to-Debt data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Y-Biologics's Cash-to-Debt Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Y-Biologics's Cash-to-Debt distribution charts can be found below:

* The bar in red indicates where Y-Biologics's Cash-to-Debt falls into.

Y-Biologics Cash-to-Debt Calculation

This is the ratio of a company's Cash, Cash Equivalents, Marketable Securities to its debt. The debt includes the Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation. This ratio measures the financial strength of a company. This ratio is updated quarterly.

Y-Biologics's Cash to Debt Ratio for the fiscal year that ended in Dec. 2022 is calculated as:

Cash to Debt Ratio	=	Cash, Cash Equivalents, Marketable Securities	/	Total Debt
	=	Cash, Cash Equivalents, Marketable Securities	/	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)
	=	12982.564	/	(4751.575	+	188.099)
	=	2.63

Y-Biologics's Cash to Debt Ratio for the quarter that ended in Mar. 2024 is calculated as:

Do not have enough data to calculate Cash to Debt ratio.

Y-Biologics (XKRX:338840) Cash-to-Debt Explanation

If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. If it is smaller than 1, it means the company has more debt than the cash in hands. In this case, it is important to look the the company's Interest Coverage. Ben Graham requires that a company must have an Interest Coverage of at least 5.

Y-Biologics Cash-to-Debt Related Terms

Thank you for viewing the detailed overview of Y-Biologics's Cash-to-Debt provided by GuruFocus.com. Please click on the following links to see related term pages.

Y-Biologics (XKRX:338840) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Y-Biologics Inc (XKRX:338840) » Definitions » Cash-to-Debt

Comparable Companies

Traded in Other Exchanges

N/A

Address

No. 715, 17, Tech-ro 4-ro, Yuseong-gu, Daejeon, KOR

Website

https://www.ybiologics.com

Y-Biologics Inc is a company has a variety of development candidate antibodies based on Korea's highest-level antibody discovery platform technology and then independently develops antibody treatments or jointly develops cutting-edge biopharmaceuticals by fusing them with our partner's platform technology. Its main business model is based on a globally competitive antibody discovery platform and consists of development of new bio drug candidates and early technology transfer, and contract research services that generate stable cash flow.

Y-Biologics (XKRX:338840) Headlines

No Headlines